Evaluate the Auxiliary Diagnostic Value of Circulating Tumor Cells in Benign and Malignant Lung Nodules

GenoSaber50 enrolled

Overview

By testing the CTC number of new solitary pulmonary nodule patient, evaluating the correlation of CTC number and benign and malignant lung nodules auxiliary diagnosis, the correlation of CTC number and the size of lung nodules of the malignant patients, the correlation between the CTC number and subtypes of malignant lung nodules patients.The CTC and tumor markers will be detected before the patient received treatment. Tumor markers include Pro-GRP, NSE, CEA, CYFRA211, SCC.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Solitary Pulmonary Nodule

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * New Solitary Pulmonary Nodule patients * first visit patient * Heart, liver and kidney function is normal. * 18-80 years old. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Blood collection time is not in the scheduled time. * The plasma sample hemolysis or condensation. * Whole blood samples less than 3 ml. * poor compliance

Outcomes

Primary Outcomes

The number of circulating tumor cells will be detected in baseline by Immunomagnetic negative screening and targeted polymerase chain reaction(PCR) method.

The 3 mL of blood will be taked with each patient for CTCs detection.

Time frame: 1 months

Secondary Outcomes

The concentration of the tumor marker of pro gastrin releasing peptide(Pro-GRP) will be detected in baseline by Electrochemical luminescence.